Silo Pharma (SILO)
Licenses preclinical CNS therapies while building QwikAgents and a cryptocurrency treasury.
Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
Follows recent European patent grant and coverage in multiple international markets as Silo continues to strengthen licensed IP portfolio for lead therapeutic program
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Expands By 795.6%
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the recipient of a large increase in short interest in July. As of July 15th, there was short interest totaling 155,110 shares, an increase of 795.6% from the June 30th total of 17,320 shares. Approximately 14.3% of the shares of the stock are sold short. Based
Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program
Silo continues to add technology assets as it expands its AI business and further develops its lead PTSD therapeutic candidate
Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform
SARASOTA, FLA. , July 14, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program.
Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request
Study designed to evaluate performance and formulation stability of proprietary nose-to-brain delivery system SARASOTA, FLA. , June 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, today announced that it has engaged its drug-device development partner Resyca to conduct a robustness study evaluating the microchip-based nasal spray system used for nose-to-brain delivery of SPC-15, the Company's lead intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).
Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial
Positive data supports the continued advancement of FDA Investigational New Drug (IND)- enabling development program SARASOTA, FLA. , June 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO) ("Silo" or "the Company"), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has confirmed the physical, chemical and microbiological stability of its investigational soft-mist intranasal prophylactic, SPC-15, through nine months of real-time testing.
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved therapies that address structural or regenerative aspects of traumatic brain injury Traumatic brain injury therapeutics market estimated to reach $6 billion by 2032 SARASOTA, FLA.
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury
New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines
Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment
Silo Pharma’s PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD
Federal initiatives focused on PTSD and related conditions appears to validate need for new and novel approaches to mental health treatment SARASOTA, Fla, April 29, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today commends a wave of coordinated U.
Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling 522,541 shares, a growth of 58.6% from the March 31st total of 329,449 shares. Based on an average trading volume of 18,681,437 shares,
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents. “We expect that Silo's diversification into AI infrastructure will enable it to take advantage of opportunities in high-growth, transformative technologies that we believe are driving the current tech economy,” said Eric Weisblum, Chief Executive Officer.
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics
SPC-15 Intranasal PTSD Program Aligns with Federal Push to Fast-Track Novel Mental Health Therapies SARASOTA, Fla. , April 20, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders.
Silo Pharma Rallies After Securing Key Patent Allowance
Silo said the European Patent Office issued a Rule 71(3) communication indicating its intent to grant a patent for the application, which the company has an exclusive license from Columbia University.
Silo Pharma (SILO) Stock Soars 47% After European Patent Win: What You Should Know
Silo Pharma stock jumps after-hours after European patent allowance for PTSD prevention therapy targeting 5-HT4 pathway.
Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy
EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio SARASOTA, FL, April 06, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University.
Silo Pharma Announces Share Buyback Program
Sarasota, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its board of directors has authorized a share repurchase program to acquire up to $1million of the Company's common stock. The Company may purchase common stock on the open market, through privately negotiated transactions, or otherwise, in compliance with the rules of the United States Securities and Exchange Commission and other applicable legal requirements. The Company had 13,318,273 shares of common stock outstanding as of November 13, 2025, as reported in its Quarterly Report for the period ended September 30, 2025.
Silo Pharma, Inc. (NASDAQ:SILO) Short Interest Update
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 518,127 shares, a drop of 12.5% from the December 31st total of 592,133 shares. Approximately 4.0% of the company's shares are sold short. Based on an
Silo Pharma (NASDAQ:SILO) Stock Price Up 3.6% – Still a Buy?
Silo Pharma, Inc. (NASDAQ: SILO - Get Free Report) shares traded up 3.6% during trading on Thursday. The stock traded as high as $0.3754 and last traded at $0.3689. 45,852 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 142,715 shares. The stock had previously closed at $0.3562.